Related Experiment Video
Updated: Dec 7, 2025
09:56
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
1.1K
Modular Chimeric Antigen Receptor Systems for Universal CAR T Cell Retargeting.
Ashley R Sutherland1, Madeline N Owens1, C Ronald Geyer2
1Department of Biochemistry, Microbiology and Immunology, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada.
International Journal of Molecular Sciences
|October 3, 2020
Summary
Modular chimeric antigen receptor (CAR) T cell technology offers flexible, programmable cancer therapies. This approach uses switch molecules for precise control and customizable T cell activity, advancing cellular immunotherapy.
Area of Science:
- Immunology and Oncology
- Cellular Therapy
- Biotechnology
Background:
- Chimeric antigen receptor (CAR) T cell therapy shows promise for anti-cancer treatment by engineering T cells to target tumor-associated antigens (TAAs).
- Traditional CAR T systems have limitations in antigen specificity and adaptability for complex cancer targets.
Purpose of the Study:
- To review advancements in universal or modular CAR T strategies.
- To highlight how these new systems enable more customizable T cell activity and expand current CAR T capabilities.
Main Methods:
- Review of emerging modular CAR T technologies that decouple targeting elements from T cell signaling domains.
- Discussion of the 'switch' molecule mechanism that controls CAR T cell activity.
Main Results:
- Modular CAR T systems allow for flexible, multi-antigen targeting and precise programming of T cell responses.
- The use of switch molecules provides dose-titratable control and enhances the safety profile of CAR T cell therapies.
Conclusions:
- Modular CAR T technology represents a significant evolution beyond fixed-specificity CAR T systems.
- These adaptable strategies pave the way for more sophisticated and personalized cellular immunotherapies.
